Key points are not available for this paper at this time.
This JAMA Forum discusses pending legislation in the US House and Senate and the history of the “firm-based approach” the US Food and Drug Administration (FDA) could use when regulating artificial intelligence (AI) medical devices to augment patient care.
Scott Gottlieb (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: